13 November2026: Imfinzi approved in the US in novel regimen with neoadjuvant Enfortumab vedotin for patients with muscle-invasive bladder cancer
AstraZeneca received US FDA approval on 13 November 2026 for Imfinzi in combination with enfortumabvedotin as neoadjuvant treatment, followed by Imfinzi monotherapy as adjuvant treatment after radical cystectomy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. The approval was supported by the Phase III VOLGAtrial following Priority Review
The approval was supported by the Phase III VOLGA trial, which randomized 695 patients across three treatment arms. The Imfinzi plus EV regimen demonstrated a 49% reduction in the risk of disease progression, recurrence, failure to undergo surgery or death (EFS HR 0.51)
The approval addresses an important unmet need in cisplatin-ineligible MIBC patients, who account for approximately 50% of this population due to impaired renal function or comorbidities. Historically, radical cystectomy alone has been the standard treatment for these patients, despite substantial recurrence risk. The newly approved perioperative regimen offers an additional treatment option to improve survival and reduce recurrence in a curative-intent setting
The regimen combines two modalities: Imfinzi, an anti-PD-L1 immune checkpoint inhibitor that blocks PD-L1 interactions with PD-1 and CD80, restoring antitumour immune responses; and enfortumab vedotin linked to the microtubule-disrupting agent monomethyl auristatin E, which induces tumour-cell death
The approval marks AstraZeneca’s third bladder cancer indication for Imfinzi in two years, strengthening its positioning as an immunotherapy backbone across muscle-invasive and non-muscle-invasive bladder cancer. The company is pursuing further regulatory approvals in the EU, Japan and other markets, potentially expanding the global commercial opportunity